Doxorubicin myelotoxicity

DOXORUBICIN AZATHIOPRINE t risk of myelosuppression and immunosuppression. Deaths have occurred following profound myelosuppression and severe sepsis. Additive myelotoxic effects. Azathioprine is metabolized to 6-mercatopurine in vivo, which results in additive myelosuppres-sion, immunosuppression and hepatotoxicity Avoid co-administration... 

No formal drug interaction studies have been conducted with pegylated liposomal doxorubicin, liposomal daunorubicin, or Myocet. Caution should be exercised when using drugs known to interact with doxorubicin or daunorubicin. Equally, caution should be exercised when giving any other cytotoxic drugs, especially myelotoxic agents, at the same time. 

High-dose ciclosporin increased the AUC of doxorubicin and doxorubicinol and produced greater doxorubicin-related myelotoxicity (244). 

High-dose ciclosporin increases the serum levels and the myelotoxicity of doxorubicin. An isolated report describes severe neurotoxicity and coma in a patient who had taken ciclosporin and was then subsequently given doxorubicin. Ciclosporin can also increase daunorubicin, epirubicin, idarubicin and mitoxantrone serum levels. 

Acute neurotoxicity and myelotoxicity occurred in a boy with Hodgkin s lymphoma treated with vinblastine, doxorubicin and methotrexate when he was also given itraconazole. The toxicity did not occur when he was given the same chemotherapy without itraconazole. ... 

---